BiotechTube
Genovac

Genovac

San Diego, United States· Est.
genovac.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Genovac is a specialized antibody discovery and development CRO/CMO with a 25-year history, originally founded in Germany and relaunched in 2020 following a management-led buyout. The company leverages proprietary genetic immunization technologies, multiple host species, and advanced single B cell screening platforms to deliver antibodies against difficult targets where traditional methods often fail. With over 3,600 completed projects, production facilities in Fargo, ND, and discovery operations in Freiburg, Germany, Genovac serves as a one-stop-shop for biotech and pharma clients aiming to accelerate their biologics pipelines.

Antibodies

Technology Platform

Proprietary genetic immunization, multiple host species (mice, rats, rabbits, llamas), and advanced single B cell screening platforms (e.g., Berkeley Lights Beacon) integrated with bioinformatics (ENPICOM IGX) for antibody discovery against challenging targets.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The growing demand for antibodies against difficult target classes like GPCRs and ion channels presents a significant niche market.
The exclusive licensing deal with Pfizer validates the platform and opens potential for future royalty revenue.
Expansion of service offerings and geographic reach can drive further growth.

Risk Factors

High competition in the CRO/CMO space requires constant technological innovation.
Dependency on key platform vendors (e.g., Berkeley Lights) creates operational risk.
Revenue is tied to client R&D budgets, which are cyclical and sensitive to biotech funding environments.

Competitive Landscape

Genovac competes with large, full-service CROs (e.g., Lonza, Charles River) and specialized antibody discovery firms (e.g., Abzena, Bio-Rad's BioLegend, Ligand's OmniAb partners). Its differentiation lies in its specific focus on challenging targets via genetic immunization and an integrated 'gene to antibody' service model.

More companies in Biologics / Biosimilars →More companies in United States →